.JPG)
The Viral Vector Purification Market Size is valued at USD 7.89 Billion in 2023 and is predicted to reach USD 21.25 Billion by the year 2031 at a 13.6% CAGR during the forecast period for 2024-2031.
Over 1,000 cell and gene therapy-related clinical trials are currently underway worldwide. Gene delivery vectors are critical in the development of cell and gene therapies since genetic manipulation is a prerequisite. So far, viral vectors (based on adeno-associated viruses (AAV), adenoviruses, lentiviruses, retroviruses, and other viruses) have been demonstrated to be the most versatile gene delivery tools available, with high transfection efficiencies in both preclinical and clinical settings. Besides that, given the therapeutic efficacy and low side effect profiles of cell and gene therapies, demand for such interventions is expected to rise rapidly, necessitating a proportional increase in demand for appropriate vector systems. Various techniques are currently used to purify viral vectors. Size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation, and size-exclusion chromatography (SEC), have become industry standards over the years.
Following the Covid-19 pandemic, many governments realized the importance of establishing research institutes in the fields of gene therapy and vaccine development. This trend of increasing investment in biotech and pharmaceutical companies is expected to boost the global market for viral vector products. Furthermore, the rising demand for synthetic genes and the untapped market potential are expected to show lucrative growth opportunities for market players in the future.
Market Segmentation:
The global viral vector purification market is segmented on the basis of product type, purification technique type, type of viral vector scope, and scale of operation. By product type, the market is segmented as a kit, prepacked column, resin, cassette, filter plate, capsule, and reagent. The other purification technique type segment includes chromatography, centrifugation, and filtration. The market is segmented by type of viral vector scope into AAV, adenovirus, lentivirus, retrovirus, and others. The scale of operation segment includes lab-scale, clinical, and commercial.
Based On The Type Of Viral Vector Scope, The AAV Segment Is Accounted As A Significant Contributor To The Global Viral Vector Purification Market.
In 2020, AAV dominated the market with a significant market share. Due to their use in the majority of cell-based gene therapies, the adeno-associated viral vector manufacturing segment is anticipated to grow at the highest CAGR during the forecast period. Some of the significant facts that enable it to occupy a significant share of this vector in the overall market are its ability to integrate with large transgenes and simple production at high levels. Several companies and state organizations have successfully developed an AAV-based vaccine to prevent Covid-19 infection.
The Clinical Segment Witnessed Growth At A Rapid Rate.
In 2020, the clinical segment had the highest market share. The rising engagement of scientific communities in gene and cell therapy research is predicted to raise demand for viral vectors due to the high need for vectors for conducting research.
Furthermore, research organisations, pharmaceutical, and biopharmaceutical enterprises are developing as significant end-users of the market for viral vectors and plasmid DNA synthesis, adding to the launch of advanced medications and the number of gene therapy-based R&D activities. One of these companies, Abeona Therapeutics, is testing AAV9-based gene therapies for CLN1 and CLN3 disorders. As a result, it will fuel market growth.
In The Region, The North American Viral Vector Purification Market Holds A Significant Revenue Share.
North America dominated the global viral vector purification market, accounting for nearly 50% of all revenue in 2020. This region has the highest demand for viral vector CDMO due to the concentration of research and development in the domain of advanced genetic therapies. The United States is the leading country in this region and the world in terms of revenue generation through ADVAC viral vector technology services. In addition, Investments made by federal agencies to expand the region's cell therapy research base are expected to boost the growth of the North American market. Besides, the Asia Pacific region is likely the fastest-growing region due to a growing patient population, increased R&D activities in this field, and other factors. Furthermore, patients from Western countries travel to Asian countries for stem cell therapy because the legal framework in this region is less restrictive.
Furthermore, the region's large population and untapped potential have resulted in a business shift for global firms in this region. Moreover, this region provides reasonably priced manufacturing and operating units for conducting research. These factors are expected to play a significant role in the expansion of the stem cell field in this region, boosting market growth even further.
Competitive Landscape
Some Major Key Players In The Viral Vector Purification Market:
- Agilent Technologies,
- BIA Separations,
- Bio-Rad Laboratories,
- BioVision, Cytiva (formerly GE Lifesciences),
- Merck,
- Sartorius,
- Takara Bio,
- Thermo Fisher Scientific.
Viral Vector Purification Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 7.89 Billion |
|
Revenue forecast in 2031 |
USD 21.25 Billion |
|
Growth rate CAGR |
CAGR of 13.6 % from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2024 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Products Type, By Purification Technique Type, By Type of Viral Vector Scope, By Scale of Operation |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Agilent Technologies, BIA Separations, Bio-Rad Laboratories, BioVision, Cytiva (formerly GE Lifesciences), Merck, Sartorius, Takara Bio, and Thermo Fisher Scientific. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
